Sandoz AG, a global leader in generic and biosimilar medicines, has announced the location of its future permanent headquarters in central Basel
The FDA has accepted a Biologics License Application (BLA) from Sandoz under the 351 (k) pathway for its pegfilgrastim biosimilar...
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Jubbonti, intended for the treatment of osteoporosis in women who have been through menopause and in men at increased risk of fractures whose bone loss is linked to hormone ablation or long-term treatment with systemic glucocorticoid.
Novartis confirmed plans for the 100% spin-off of the Sandoz business, with trading of new Sandoz Group AG shares and ADRs (American Depositary Receipts) to commence on October 4, 2023
Novartis announced its intention to separate Sandoz, its generics and biosimilars division into a new publicly traded standalone company, by way of a 100% spin-off
Sandoz, announced that it will not pursue its submission for biosimilar rituximab in the US at this time. The decision...
Sandoz announced that the FDA has accepted its Biologics License Application (BLA) under the 351(k) pathway for its proposed biosimilar...
The Sandoz application for a marketing authorisation at EMA for Zioxtenzo (pegfilgrastim biosimilar) has been withdrawn. Zioxtenzo was developed as...
Sandoz announced that the FDA has accepted its Biologics License Application for filgrastim, which was filed under the new biosimilar...
Sandoz, announced that the European Commission (EC) has approved a type II variation for the addition of a subcutaneous (s.c.)...